R. Hashizume

DIPG-24. BRD4 INHIBITION AS A RADIOSENSITIZER THROUGH BLOCKING DNA REPAIR FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
20230 citationsauthor #9
WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas
20235 citationsauthor #4
DIPG-17. TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA USING ALLELE-SPECIFIC SIRNA TARGETING H3.3 K27M MUTANT HISTONE
20230 citationsauthor #13
FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells
202323 citationsauthor #7
Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations
202310 citationsauthor #13
DIPG-18. AI HUNTING FOR NEW DRUGS IN PEDIATRIC GLIOMA
20230 citationsauthor #1
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
202230 citationsauthor #6
The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science
202259 citationsauthor #66
EXTH-82. THERAPEUTIC TARGETING OF EZH2 AND BET BRD4 IN PEDIATRIC RHABDOID TUMORS
20220 citationsauthor #12
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma
202237 citationsauthor #14
Immunotherapy approaches for the treatment of diffuse midline gliomas
202226 citationsauthor #15
Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma
202216 citationsauthor #16
LW-10 PRECLINICAL THERAPEUTIC TESTING FOR BRAIN TUMOR USING PATIENT-DERIVED XENOGRAFT (PDX) MODEL
20220 citationsauthor #1
EXTH-08. DEVELOPMENT OF NOVEL HISTONE DEMETHYLASE INHIBITOR AGAINST DIPG
20220 citationsauthor #9
Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumor.
202217 citationsauthor #15
Identification and Characterization of a Novel Brain-Penetrant Indoleamine 2,3 Dioxygenase 1 Protein Degrader for Glioblastoma
20221 citationsauthor #13
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
20222 citationsauthor #6
A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell‐of‐origin dependent effects of H3K27M
202229 citationsauthor #8
Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma.
20227 citationsauthor #11
Epigenome programing by H3.3K27M mutation creates a dependence of pediatric glioma on SMARCA4.
202224 citationsauthor #13
EXTH-29. RADIOSENSITIZATION BY BRD4 INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA
20220 citationsauthor #7
WDR82 mediated H3K4me3 is associated with tumor proliferation and therapeutic efficacy in pediatric high-grade gliomas
20220 citationsauthor #4
Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors
20215 citationsauthor #5
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
202112 citationsauthor #17
The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
202115 citationsauthor #4
DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA
20201 citationsauthor #17
Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma
202045 citationsauthor #15
HGG-26. H3G34V MUTATION AFFECTS GENOMIC H3K36 METHYLATION IN PEDIATRIC GLIOMA
20200 citationsauthor #5
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
202048 citationsauthor #23
DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
20201 citationsauthor #5
ET-03 Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse midline glioma
20200 citationsauthor #6
DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG
20200 citationsauthor #21
LSD1 Inhibition in pHGG: The key to unleashing immunotherapy?
20201 citationsauthor #2
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
202033 citationsauthor #9
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
202053 citationsauthor #13
Bone morphogenetic protein 4 reduces global H3K4me3 to inhibit proliferation and promote differentiation of human neural stem cells
20200 citationsauthor #7
DDRE-15. THE COMBINATION THERAPY OF PARP INHIBITOR AND TMZ IN DIFFUSE MIDLINE GLIOMA HARBORING H3 K27M-MUTANT
20200 citationsauthor #2
Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
202012 citationsauthor #5
MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma
20201 citationsauthor #14
ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
201917 citationsauthor #2
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
2019189 citationsauthor #37
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis
201996 citationsauthor #8
PDTM-34. RADIOSENSITIZATION BY BRD4 INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA
20194 citationsauthor #7
Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
201958 citationsauthor #14
DIPG-26. ACVR1 R206H COOPERATES WITH H3.1K27M IN PROMOTING DIFFUSE INTRINSIC PONTINE GLIOMA PATHOGENESIS
20190 citationsauthor #8
PDTM-31. INVESTIGATING THE EFFECT OF H3G34V MUTATION ON DISTINCT GENOMIC H3K36 METHYLATION PATTERNS IN PEDIATRIC GLIOMA
20190 citationsauthor #6
Potent Antineoplastic Effects of Combined PI3Kα–MNK Inhibition in Medulloblastoma
201913 citationsauthor #12
Abstract 2871: Global reduction of H3K4me3 improves chemotherapeutic efficacy for pediatric ependymomas
20190 citationsauthor #3
Molecular and translational advances in meningiomas.
2019113 citationsauthor #7
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
201961 citationsauthor #24
Identification of novel RAS signaling therapeutic vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
201919 citationsauthor #21
DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG
20190 citationsauthor #13
Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas
201912 citationsauthor #4
EXTH-60. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
20191 citationsauthor #4
ATRT-02. THERAPEUTIC TARGETING OF EZH2 AND BET BRD4 IN AT/RT
20192 citationsauthor #11
Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease
201933 citationsauthor #6
HGG-10. HISTONE H3G34V MUTATION IS SUFFICIENT TO DRIVE DISTINCT GENOMIC H3K36 METHYLATION PATTERNS IN PEDIATRIC GLIOMA
20190 citationsauthor #6
PDTM-10. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA
20180 citationsauthor #8
PDTM-42. TARGETED INHIBITION OF BET BROMODOMAIN AND JMJD3 PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
20180 citationsauthor #16
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy
2018157 citationsauthor #17
DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA
20180 citationsauthor #10
IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA
20181 citationsauthor #8
DIPG-55. TARGETING SENESCENT CELLS WITH ABT-263 ENHANCES CELL DEATH INDUCED BY BMI1 INHIBITION AND IONIZING RADIATION IN DIPG
20180 citationsauthor #10
Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy.
201897 citationsauthor #13
DIPG-33. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38
20181 citationsauthor #8
PDTM-05. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG
20180 citationsauthor #19
PDTM-29. CSF H3F3A K27M CIRCULATING TUMOR DNA COPY NUMBER QUANTIFIES TUMOR GROWTH AND TREATMENT RESPONSE
20180 citationsauthor #9
DIPG-24. TARGETED INHIBITION OF JMJD3 AND BET BROMODOMAIN PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS
20180 citationsauthor #13
Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging
201814 citationsauthor #2
New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model
201826 citationsauthor #10
EPEN-30. HISTONE H3 LYSINE 4 TRIMETHYLATION IS A POTENTIAL TARGET TO IMPROVE CHEMOTHERAPEUTIC EFFICACY FOR PEDIATRIC PRIMARY EPENDYMOMAS
20180 citationsauthor #4
NIMG-73. RADIOMICS OF GLIOBLASTOMA FOR PREDICTING MGMT PROMOTOR METHYLATION STATUS AND PROGNOSIS
20181 citationsauthor #14
DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES
20180 citationsauthor #11
PDTM-39. HISTONE H3 MUTATION EFFECTS ON CHROMATIN STRUCTURE AND REGULATION OF GENE TRANSCRIPTION IN PEDIATRIC GLIOMA
20180 citationsauthor #7
CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response
201865 citationsauthor #11
DIPG-14. INTEGRATED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) NEXT-GENERATION SEQUENCING REVEALS EPIGENETIC DYSREGULATION OF GENE EXPRESSION AND BROMODOMAIN INHIBITION AS A NOVEL THERAPEUTIC TARGET
20180 citationsauthor #8
DIPG-63. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG
20180 citationsauthor #20
Inhibition inDiffuse Intrinsic PontineGlioma
20180 citationsauthor #12
MELK Inhibition in Diffuse Intrinsic Pontine Glioma
201837 citationsauthor #10
IMMU-24. IMMUNOTHERAPEUTIC NANOTECHNOLOGY TARGETING IDO1 FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA
20182 citationsauthor #7
Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma
201733 citationsauthor #4
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
2017353 citationsauthor #2
DIPG-24. EPIGENETIC ANALYSIS OF FORMALIN-FIXED PARAFFIN-EMBEDDED PEDIATRIC GLIOMA TISSUE
20170 citationsauthor #3
IMMU-21. CHARACTERIZING IDO1 AND ITS THERAPEUTIC POTENTIAL IN PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS.
20172 citationsauthor #4
DIPG-19. MESENCHYMAL STEM CELLS TARGET DIFFUSE INTRINSIC PONTINE GLIOMA IN MICE AFTER INTRANASAL DELIVERY
20170 citationsauthor #6
Therapeutic Hypothesis Testing With Rodent Brain Tumor Models
201710 citationsauthor #3
A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.
201734 citationsauthor #11
PDTM-36. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38
20171 citationsauthor #7
DIPG-28. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG.
20170 citationsauthor #11
Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
201733 citationsauthor #3
Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma
201746 citationsauthor #1
PDTM-28. TARGETED INHIBITION OF EZH2 AND BET BROMODOMAIN PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS
20172 citationsauthor #18
Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies
201739 citationsauthor #2
DIPG-36. NOVEL THERAPEUTIC APPROACHES USING NANOLIPOSMAL SN-38 FOR THE TREATMENT OF HUMAN BRAINSTEM GLIOMA
20170 citationsauthor #3
IMMU-46. A siRNA APPROACH FOR TARGETING IMMUNOSUPPRESSIVE IDO1 IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA
20170 citationsauthor #6
Therapeutic Hypothesis Testing With Rodent Brain Tumor Models
20170 citationsauthor #3
DIPG-25. IN VITRO AND IN VIVO ANALYSIS OF TENASCIN-C EXPRESSION IN PEDIATRIC BRAINSTEM GLIOMA
20171 citationsauthor #3
P11.01 Intranasal delivery of mesenchymal stem cells targets diffuse intrinsic pontine glioma in mouse model.
20170 citationsauthor #6
PDTM-02. NEXT-GENERATION SEQUENCING OF DIFFUSE INTRINSIC PONTINE GLIOMA CELLS REVEALS ALTERED EPIGENETIC REGULATION AND DISTINCT TUMOR SUBGROUPS
20170 citationsauthor #6
Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG
2017138 citationsauthor #8

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT